- $1.23m
- -$8.23m
- $0.67m
- 36
- 56
- 36
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.12 | ||
| Price to Tang. Book | 0.12 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.84 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -137.89% | ||
| Return on Equity | -76.73% | ||
| Operating Margin | -2389.19% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.93 | 7.3 | 5.75 | 1.15 | 0.67 | n/a | n/a | -53.03% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vyant Bio, Inc. has no continuing operating activities other than the winddown and closure of its business. The Company is seeking to obtain its shareholders’ approval for the voluntary liquidation and dissolution of the Company, pursuant to a plan of liquidation and dissolution.
Directors
- John Fletcher CHM (58)
- John Roberts PRE (61)
- Andrew LaFrence CFO
- Ralf Brandt CEX (53)
- Barb Jones SVP
- Marcus Boehm DRC
- Paul Hansen DRC
- Joanna Horobin DRC
- Yung-Ping Yeh DRC
- Geoffrey Harris IND
- Howard McLeod IND (54)
- Last Annual
- December 31st, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- April 8th, 1999
- Public Since
- April 10th, 2013
- No. of Shareholders
- 81
- No. of Employees
- 8
- Sector
- Holding Companies
- Industry
- Financials
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 6,328,752
- Address
- 2 Executive Campus, CHERRY HILL, 08002
- Web
- https://www.vyantbio.com/
- Phone
- +1 2015289200
- Contact
- Andrew Lafrence
- Auditors
- Deloitte & Touche LLP
Upcoming Events for VYNT
Similar to VYNT
12 Retech
Pink Sheets on Nasdaq
1399 Internet Technology Application
Pink Sheets on Nasdaq
3D Pioneer Systems
Pink Sheets on Nasdaq
9 Meters Biopharma
Pink Sheets on Nasdaq
A1
Pink Sheets on Nasdaq
FAQ
What is the Vyant Bio share price?
As of Today at 18:23 UTC, shares in Vyant Bio are trading at $0.19. This share price information is delayed by 15 minutes.
How has the Vyant Bio share price performed this year?
Shares in Vyant Bio last closed at $0.19 and the price had moved by -72.29% over the past 365 days. In terms of relative price strength the Vyant Bio share price has underperformed the S&P500 Index by -76.81% over the past year.
What are the analyst and broker recommendations for Vyant Bio?
The overall consensus recommendation for Vyant Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Vyant Bio dividend yield?
Vyant Bio does not currently pay a dividend.
Does Vyant Bio pay a dividend?
Vyant Bio does not currently pay a dividend.
When does Vyant Bio next pay dividends?
Vyant Bio does not currently pay a dividend.
How do I buy Vyant Bio shares?
To buy shares in Vyant Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vyant Bio?
As of the previous close price of $0.19, shares in Vyant Bio had a market capitalisation of $1.23m.
Where are Vyant Bio shares listed?
Here are the trading details for Vyant Bio:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: VYNT
What kind of share is Vyant Bio?
Based on an overall assessment of its quality, value and momentum Vyant Bio is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vyant Bio share price forecast for 2024?
The analyst consensus target price for shares in Vyant Bio is $5.00. That is 2477.32% above the last closing price of $0.19.
Analysts covering Vyant Bio currently have a consensus Earnings Per Share (EPS) forecast of -$2.38 for the next financial year.
What is the trend in the Vyant Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vyant Bio. Over the past six months, its share price has underperformed the S&P500 Index by -8.7%.
As of the last closing price of $0.19, shares in Vyant Bio were trading -25.65% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vyant Bio PE Ratio?
The Vyant Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vyant Bio?
Vyant Bio's management team is headed by:
- John Fletcher - CHM
- John Roberts - PRE
- Andrew LaFrence - CFO
- Ralf Brandt - CEX
- Barb Jones - SVP
- Marcus Boehm - DRC
- Paul Hansen - DRC
- Joanna Horobin - DRC
- Yung-Ping Yeh - DRC
- Geoffrey Harris - IND
- Howard McLeod - IND